Normal Cholesterol, But the Risk Is There: What DNA Reveals

A lipid panel can look perfectly fine: low-density lipoprotein (LDL) not elevated, high-density lipoprotein (HDL) sufficient, total cholesterol within reference values. On paper, this looks like a favorable profile. But in clinical practice, normal numbers don't always mean low cardiovascular risk.

In some people, the first cardiovascular event occurs against a backdrop of normal test results. This means a lipid panel reflects the current concentration of lipids in the blood, but doesn't fully capture long-term susceptibility to atherosclerosis.

According to research, including approaches to integrating genetic risk indices (Honigberg & Faaborg-Andersen, 2023) and large population-based analyses (Iribarren et al., 2022; Benn et al., 2024), genetic predisposition can substantially alter cardiovascular risk even at optimal LDL levels.

This is where the limitation of a standard lipid panel becomes apparent — the gap between the number and the processes forming over decades within the vessel wall.

What a Lipid Panel Shows — and What It May Miss

A lipid panel measures lipid concentrations in blood plasma at a specific moment in time. It answers the question "how much," but not "why" or "how is it regulated."

Results depend on diet, sleep, and physical activity in the days prior. It's a useful snapshot, but it doesn't show the efficiency of LDL clearance from the blood, the functionality of HDL, or the presence of chronic vascular inflammation even when values are normal.

These processes are partly determined by genetic regulation of lipid metabolism. For example, variants in the LDLR–PCSK9 system affect the rate of LDL clearance, and changes in APOA1 are associated with the quality of HDL's anti-atherogenic function (Supajaree et al., 2022).

Additionally, inflammatory and metabolic biomarkers are considered in the context of vascular risk — including homocysteine, the level of which may be linked to inherited features of B-vitamin metabolism.

Learn more about the role of homocysteine in cardiovascular risk — see the article on B vitamins and genetics.

Why the Same LDL Level Can Mean Different Cardiovascular Risk

Imagine two people of the same age, with similar lifestyles and nearly identical lipid panel results. Yet they carry individual genetic features that affect how their bodies produce, transport, and clear cholesterol — which is precisely why their long-term cardiovascular risk may differ.

The key mechanism is the clearance of LDL from the blood via liver receptors. The protein PCSK9 regulates the number of these receptors: the higher its activity, the fewer LDLR receptors on the cell surface, and the slower the clearance of LDL from the blood.

HDL also has a functional dimension: what matters is not only its concentration, but the efficiency of reverse cholesterol transport. This is partly linked to variants in genes regulating the ApoA1 protein and its associated metabolic pathways.

Thus, the same lab value can reflect different underlying biological mechanisms.

Read more about general cardiac risk factors — see the article on cardiovascular health.

Genetic Risk: When "Normal" Doesn't Mean Safe

Polygenic Risk Score (PRS) is an integrated measure that accounts for hundreds to thousands of genetic variants associated with cardiovascular risk.

According to consensus reviews from the American Heart Association (Trinder et al., 2023) and population-based studies (Iribarren et al., 2022; Benn et al., 2024), PRS allows for individualization of cardiovascular disease risk even in people with optimal LDL levels.

Individuals with high PRS show elevated relative risk of ischemic heart disease even with LDL < 100 mg/dL. Conversely, low genetic risk can shift the baseline probability downward even with moderately elevated LDL levels.

This doesn't mean cholesterol levels don't matter. It means that the same number carries different significance depending on genetic background (Honigberg & Faaborg-Andersen, 2023).

Lipid Panel and Genetic Profile: Different Layers of Information

Lipid Panel:

• LDL, HDL, and triglyceride concentrations

• Current state at a specific point in time

Genetic Profile:

• Mechanisms of lipid metabolism regulation

• LDL clearance efficiency

• Functional characteristics of HDL

• Predisposition to vascular inflammation

PRS:

• Integrated assessment of hereditary predisposition

• Relative risk in population context

These approaches don't compete — they complement each other.

A lipid panel shows the state.

Genetics reveals the mechanism. PRS — long-term predisposition.

What DNA Analysis Adds to Standard Assessmen

The Apixmed Prism "Cardiovascular System" DNA test analyzes 20 markers across three categories:

Cardiovascular diseases

Eight markers reflecting genetic predisposition to major cardiovascular conditions: hypertension, heart attack, coronary artery disease, stroke, arrhythmia, aneurysm, and varicose veins.

Metabolic risks

Five markers characterizing metabolic cardiovascular risk factors, including salt sensitivity and genetic features associated with non-alcoholic fatty liver disease (NAFLD), gout, aerobic capacity, and VO₂max.

Lipids and inflammatory markers

Seven markers that form a genetic profile of lipid metabolism and vascular inflammation, including total cholesterol, HDL, apolipoprotein A1, homocysteine, C-reactive protein, and genetic factors related to glucose and lipid metabolism disorders.

The result of a genetic test is not a diagnosis and does not replace clinical assessment. It is context that helps explain why bodies respond differently to the same factors and where preventive attention is warranted.

Explore your genetic lipid metabolism profile → DNA test "Cardiovascular System"

Risk Is Defined Not by Numbers, but by Mechanisms

Normal cholesterol is a positive signal — but not a complete answer.

Cardiovascular risk is shaped not only by lipid concentrations, but by how the body regulates them: the rate of LDL clearance, the effectiveness of HDL's protective function, and predisposition to vascular inflammation.

These mechanisms are partly genetically determined and remain stable throughout life. That is why a lipid panel and a genetic profile provide different but complementary layers of information.

Together, they allow a shift from asking "is there an abnormality" to understanding "how is risk forming" — enabling well-informed decisions in support of long-term health.

Genetic test results are not a diagnosis and do not replace a physician's consultation. They provide additional genetic context that may be used alongside clinical assessment to support preventive decision-making.

References

• Honigberg MC, Faaborg-Andersen C. (2023). Integrating Indices of Genetic Risk for Cardiovascular Disease. JACC Advances, 2(8):100568. https://doi.org/10.1016/j.jacadv.2023.100568

• Iribarren C et al. (2022). Joint Consideration of LDL-C and Polygenic Risk for Coronary Heart Disease Risk Assessment. Circ Genom Precis Med, 15(5):e003767. https://doi.org/10.1161/CIRCGEN.122.003767

• Trinder M et al. (2023). Polygenic Risk Scores for Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation, 148(19):1471–1499. https://doi.org/10.1161/CIR.0000000000001077

• Benn M et al. (2024). Polygenic risk of high LDL cholesterol and ischemic heart disease in the general population. Atherosclerosis, 398:117634. https://doi.org/10.1016/j.atherosclerosis.2024.117634

• Liu M et al. (2025). Genetic Variants, Bioactive Compounds, and PCSK9 Inhibitors in Hyper-LDL-Cholesterolemia. Nutrients, 17(9):1411. https://doi.org/10.3390/nu17091411

• Supajaree P et al. (2022). Association between ApoA1 Gene, Plasma Lipid Profile, hsCRP Level, and Risk of Arterial Stiffness in Thai Elderly. Biomed Res Int, 2022:4930033. https://doi.org/10.1155/2022/4930033